Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke

Nature Medicine

Volumn 14, Issue 7, 2008, Pages 731-737

  Su, Enming J ^a   Fredriksson, Linda ^b   Geyer, Melissa ^a   Folestad, Erika ^b   Cale, Jacqueline ^a   Andrae, Johanna ^b   Gao, Yamei ^c   Pietras, Kristian ^b   Mann, Kris ^a   Yepes, Manuel ^d   Strickland, Dudley K ^c   Betsholtz, Christer ^b   Eriksson, Ulf ^b   Lawrence, Daniel A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; IMATINIB; NEUTRALIZING ANTIBODY; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR C; PLATELET DERIVED GROWTH FACTOR CC; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; BLOOD VESSEL PERMEABILITY; BRAIN BLOOD VESSEL; CELL CULTURE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; HEMOGLOBIN DETERMINATION; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; BRAIN ISCHEMIA; FIBRINOLYTIC AGENTS; LYMPHOKINES; MICE; MICE, INBRED C57BL; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

MUS;

EID: 46749118298     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1787     Document Type: Article

References (45)

1. Thom, T. et al. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113, e85-e151 (2006).
2. Hou, S.T. & MacManus, J.P. Molecular mechanisms of cerebral ischemia-induced neuronal death. Int. Rev. Cytol. 221, 93-148 (2002).
3. Marler, J.R. & Goldstein, L.B. Medicine. Stroke - tPA and the clinic. Science 301, 1677 (2003).
4. Tsirka, S.E., Gualandris, A., Amaral, D.G. & Strickland, S. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 377, 340-344 (1995).
5. Tsirka, S.E., Rogove, A.D., Bugge, T.H., Degen, J.L. & Strickland, S. An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J. Neurosci. 17, 543-552 (1997).
6. Wang, Y.F. et al. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat. Med. 4, 228-231 (1998).
7. Nagai, N., De Mol, M., Lijnen, H.R., Carmeliet, P. & Collen, D. Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. Circulation 99, 2440-2444 (1999).
8. Yepes, M. et al. Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood 96, 569-576 (2000).
9. Nicole, O. et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat. Med. 7, 59-64 (2001).
10. Cinelli, P. et al. Neuroserpin, a neuroprotective factor in focal ischemic stroke. Mol. Cell. Neurosci. 18, 443-457 (2001).
11. Yepes, M. et al. Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent. J. Clin. Invest. 109, 1571-1578 (2002).
12. Pawlak, R., Melchor, J.P., Matys, T., Skrzypiec, A.E. & Strickland, S. Ethanol-withdrawal seizures are controlled by tissue plasminogen activator via modulation of NR2B-containing NMDA receptors. Proc. Natl. Acad. Sci. USA 102, 443-448 (2005).
13. Tabrizi, P. et al. Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background. Arterioscler. Thromb. Vasc. Biol. 19, 2801-2806 (1999).
14. Zivin, J.A., Fisher, M., DeGirolami, U., Hemenway, C.C. & Stashak, J.A. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science 230, 1289-1292 (1985).
15. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 333, 1581-1587 (1995).
16. Zhang, Z. et al. Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke. Circulation 106, 740-745 (2002).
17. Yepes, M. et al. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J. Clin. Invest. 112, 1533-1540 (2003).
18. Herz, J. LRP: a bright beacon at the blood-brain barrier. J. Clin. Invest. 112, 1483-1485 (2003).
19. Wang, X. et al. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat. Med. 9, 1313-1317 (2003).
20. Fredriksson, L., Li, H., Fieber, C., Li, X. & Eriksson, U. Tissue plasminogen activator is a potent activator of PDGF-CC. EMBO J. 23, 3793-3802 (2004).
21. Li, X. et al. PDGF-C is a new protease-activated ligand for the PDGF-α receptor. Nat. Cell Biol. 2, 302-309 (2000).
22. Fredriksson, L., Ehnman, M., Fieber, C. & Eriksson, U. Structural requirements for activation of latent platelet-derived growth factor CC by tissue plasminogen activator. J. Biol. Chem. 280, 26856-26862 (2005).
23. Hart, C.E. et al. Two classes of PDGF receptor recognize different isoforms of PDGF. Science 240, 1529-1531 (1988).
24. Polavarapu, R. et al. Tissue-type plasminogen activator-mediated shedding of astrocytic low-density lipoprotein receptor-related protein increases the permeability of the neurovascular unit. Blood 109, 3270-3278 (2007).
25. Willnow, T.E. & Herz, J. Genetic deficiency in low density lipoprotein receptor-related protein confers cellular resistance to Pseudomonas exotoxin A. Evidence that this protein is required for uptake and degradation of multiple ligands. J. Cell Sci. 107, 719-726 (1994).
26. Yu, H. et al. Control elements between -9.5 and -3.0 kb in the human tissue-type plasminogen activator gene promoter direct spatial and inducible expression to the murine brain. Eur. J. Neurosci. 14, 799-808 (2001).
27. Hamilton, T.G., Klinghoffer, R.A., Corrin, P.D. & Soriano, P. Evolutionary divergence of platelet-derived growth factor α receptor signaling mechanisms. Mol. Cell. Biol. 23, 4013-4025 (2003).
28. Ding, H. et al. A specific requirement for PDGF-C in palate formation and PDGFR-α signaling. Nat. Genet. 36, 1111-1116 (2004).
29. Wolf, B.B., Lopes, M.B., VandenBerg, S.R. & Gonias, S.L. Characterization and immunohistochemical localization of α 2-macroglobulin receptor (low-density lipoprotein receptor-related protein) in human brain. Am. J. Pathol. 141, 37-42 (1992).
30. Nagai, N. et al. Tissue-type plasminogen activator has paradoxical roles in focal cerebral ischemic injury by thrombotic middle cerebral artery occlusion with mild or severe photochemical damage in mice. J. Cereb. Blood Flow Metab. 22, 648-651 (2002).
31. Nagai, N., Suzuki, Y., Van, H.B., Lijnen, H.R. & Collen, D. Effects of plasminogen activator inhibitor-1 on ischemic brain injury in permanent and thrombotic middle cerebral artery occlusion models in mice. J. Thromb. Haemost. 3, 1379-1384 (2005).
32. Capdeville, R., Buchdunger, E., Zimmermann, J. & Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1, 493-502 (2002).
33. The National Institute of Neurological Disorders and Stroke t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 28, 2109-2118 (1997).
34. Larrue, V., von Kummer, R.R., Muller, A. & Bluhmki, E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 32, 438-441 (2001).
35. Thomalla, G. et al. Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia: MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours. Stroke 38, 313-318 (2007).
36. Vora, N.A. et al. Factors predicting hemorrhagic complications after multimodal reperfusion therapy for acute ischemic stroke. AJNR Am. J. Neuroradiol. 28, 1391-1394 (2007).
37. Yepes, M. & Lawrence, D.A. New functions for an old enzyme: nonhemostatic roles for tissue-type plasminogen activator in the central nervous system. Exp. Biol. Med. (Maywood) 229, 1097-1104 (2004).
38. Yepes, M. & Lawrence, D.A. Tissue-type plasminogen activator and neuroserpin: a well balanced act in the nervous system? Trends Cardiovasc. Med. 14, 173-180 (2004).
39. Zhuo, M. et al. Role of tissue plasminogen activator receptor LRP in hippocampal longterm potentiation. J. Neurosci. 20, 542-549 (2000).
40. Hao, Z. et al. New transgenic evidence for a system of sympathetic axons able to express tissue plasminogen activator (t-PA) within arterial/arteriolar walls. Blood 108, 200-202 (2006).
41. Gualandris, A., Jones, T.E., Strickland, S. & Tsirka, S.E. Membrane depolarization induces calcium-dependent secretion of tissue plasminogen activator. J. Neurosci. 16, 2220-2225 (1996).
42. Breedveld, P. et al. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res. 65, 2577-2582 (2005).
43. Melchor, J.P. & Strickland, S. Tissue plasminogen activator in central nervous system physiology and pathology. Thromb. Haemost. 93, 655-660 (2005).
44. Ponten, A. et al. Transgenic overexpression of platelet-derived growth factor-C in the mouse heart induces cardiac fibrosis, hypertrophy, and dilated cardiomyopathy. Am. J. Pathol. 163, 673-682 (2003).
45. McMahon, G.A. et al. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J. Biol. Chem. 276, 33964-33968 (2001).